A Randomized, Placebo-controlled, Double-blind, Multiple Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ 61393215 in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2017
At a glance
- Drugs JNJ 61393215 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 22 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.
- 12 Apr 2017 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017.